Related Experiment Video
Updated: Jul 20, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome
T Kaserer1, V Obermoser2, A Weninger2
1Computer-Aided Molecular Design Group, Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.
Abstract:
The peroxisome proliferator-activated receptor (PPAR) γ regulates the expression of genes involved in adipogenesis, lipid homeostasis, and glucose metabolism, making it a valuable drug target. However, full activation of the nuclear receptor is associated with unwanted side effects. Research therefore focuses on the discovery of novel partial agonists, which show a distinct protein-ligand interaction pattern compared to full agonists. Within this study, we employed pharmacophore- and shape-based virtual screening and docking independently and in parallel for the identification of novel PPARγ ligands. The ten top-ranked hits retrieved with every method were further investigated with external in silico bioactivity profiling tools. Subsequent biological testing not only confirmed the binding of nine out of the 29 selected test compounds, but enabled the direct comparison of the method performances in a prospective manner. Although all three methods successfully identified novel ligands, they varied in the numbers of active compounds ranked among the top-ten in the virtual hit list. In addition, these compounds were in most cases exclusively predicted as active by the method which initially identified them. This suggests, that the applied programs and methods are highly complementary and cover a distinct chemical space of PPARγ ligands. Further analyses revealed that eight out of the nine active molecules represent novel chemical scaffolds for PPARγ, which can serve as promising starting points for further chemical optimization. In addition, two novel compounds, identified with docking, proved to be partial agonists in the experimental testing.
Insights
Researchers identified novel partial agonists for peroxisome proliferator-activated receptor gamma (PPARγ) using virtual screening and docking. This approach aids in discovering new drug candidates with potentially fewer side effects.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Molecular Pharmacology
Background:
- Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of adipogenesis, lipid, and glucose metabolism.
- Full PPARγ activation leads to undesirable side effects, driving research into partial agonists.
- Partial agonists offer a distinct interaction profile, presenting a safer therapeutic avenue.
Purpose of the Study:
- To identify novel partial agonists of PPARγ using computational methods.
- To compare the efficacy of pharmacophore-, shape-based virtual screening, and docking in identifying PPARγ ligands.
- To discover novel chemical scaffolds for PPARγ drug development.
Main Methods:
- Employed pharmacophore- and shape-based virtual screening, and molecular docking.
- Selected top-ranked hits for in silico bioactivity profiling.
- Conducted biological testing to validate predicted PPARγ ligands.
Main Results:
- Nine out of 29 tested compounds confirmed binding to PPARγ.
- All three computational methods identified novel ligands, with varying success rates.
- Eight novel chemical scaffolds for PPARγ were discovered.
- Two compounds identified via docking demonstrated partial agonism.
Conclusions:
- Pharmacophore-, shape-based virtual screening, and docking are complementary methods for PPARγ ligand discovery.
- The identified novel scaffolds offer promising starting points for PPARγ-targeted drug optimization.
- Discovery of partial agonists via computational screening paves the way for safer therapeutics.
More Related Videos
12:22A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
Published on: September 22, 2019
09:03Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
Published on: March 10, 2020